Bristol-Myers Transplant Drug Backed by FDA Panel

by Rajshri on  March 2, 2010 at 9:38 PM Drug News   - G J E 4
 Bristol-Myers Transplant Drug Backed by FDA Panel
An organ transplant drug from Bristol-Myers Squibb Co called as belatacept has received backing from an expert panel of the Food and Drug Administration. The panel voted 13-5 in favor of the drug, which is given to organ transplant recipients to prevent rejection.

Bristol's drugs is thought to be better than older drugs, which caused headaches, nausea and liver toxicity. In a study, patients on belatacept had improved kidney function and lower blood pressure, which are key indicators of survival.

The FDA is not required to follow the panel's recommendations, but it usually does so.

Source: Medindia

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like